Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 1/20 | 0.34 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.32 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | PDE2A | O00408 | 3/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16736712 | 0.81 | EPHX1 (0.34) | APPKCNH2TMEM97SIGMAR1PDE2A | |
| SCHEMBL16748387 | 0.79 | ADRA1D (0.32) | CNR2 | |
| SCHEMBL18272073 | 0.77 | NOTUM (0.33) | CNR2PDE2A | |
| SCHEMBL16736699 | 0.76 | ACHE (0.40) | KCNK3KCNK9APP | |
| SCHEMBL18271995 | 0.75 | ALOX15 (0.37) | KCNH2TMEM97SIGMAR1CNR2 | |
| SCHEMBL16736695 | 0.74 | GABRA1 (0.36) | — | |
| SCHEMBL18272129 | 0.72 | HTR2A (0.34) | EPHX1 | |
| SCHEMBL18272175 | 0.71 | CNR2 (0.33) | CNR2 | |
| SCHEMBL16736861 | 0.71 | LMNA (0.42) | — | |
| SCHEMBL16736717 | 0.71 | GABRA1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016190871-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | TANSNA THERAPEUTICS, INC. (US) | 2016-12-01 | — | — | WO | claimed |
| US-20170174600-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | TANSNA THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170174600-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | TANSNA THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170174600-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | TANSNA THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-9630896-B2 | 2,5-dialkyl-4-H/halo/ether-phenol compounds | TANSNA THERAPEUTICS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-9630896-B2 | 2,5-dialkyl-4-H/halo/ether-phenol compounds | TANSNA THERAPEUTICS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-9630896-B2 | 2,5-dialkyl-4-H/halo/ether-phenol compounds | TANSNA THERAPEUTICS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| WO-2016190871-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | TANSNA THERAPEUTICS, INC. (US) | 2016-12-01 | — | — | WO | disclosed |
| WO-2016190871-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | TANSNA THERAPEUTICS, INC. (US) | 2016-12-01 | — | — | WO | disclosed |
| US-20150148430-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | TANSNA THERAPEUTICS, INC. | 2015-05-28 | — | — | US | disclosed |
| US-20150148430-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | TANSNA THERAPEUTICS, INC. | 2015-05-28 | — | — | US | disclosed |
| US-20150148430-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | TANSNA THERAPEUTICS, INC. | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174600-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | COMT, DDT, TYR | KCNK3 231/4885KCNK9 147/4885APP 1608/4885 |
| US-20150148430-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | COMT, DDT, TYR | KCNK3 231/4885KCNK9 147/4885APP 1608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.